A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.04-28

Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630343317?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-28 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630343317","market":"nz","top_or_hot":-1,"title":"A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS","media":"Simply Wall St.","content":"<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 05:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMA","symbol_name":"Emera Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","article_id":"2630343317","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630343317","pubTimestamp":1777324015,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia syndrome in Europe.\nSee our latest analysis for Arrowhead Pharmaceuticals.\nThe CHMP opinion comes after a powerful run in the shares, with a 1 month share price return of 27.92% and a 7 day gain of 6.73%. The 1 year total shareholder return is very large, suggesting momentum has been building...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMA":"Emera Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4087":"商业印刷","BK4139":"生物科技","CHMP":"冠军工业","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4081":"电力公用事业","ARWR":"Arrowhead Research Corporation"},"translate_title":"EMA CHMP支持FCS Redemplo后Arrowhead Pharmaceuticals(ARWR)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMA":1.5,"DCF":1,"ARWR":1.5,"CHMP":1.5},"content_text":"Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia syndrome in Europe. See our latest analysis for Arrowhead Pharmaceuticals. The CHMP opinion comes after a powerful run in the shares, with a 1 month share price return of 27.92% and a 7 day gain of 6.73%. The 1 year total shareholder return is very large, suggesting momentum has been building around the REDEMPLO story and broader RNAi pipeline expectations. If this kind of biotech catalyst interests you, it could be worth widening your search using our screener of 33 healthcare AI stocks With Arrowhead shares already up sharply and the stock trading at a sizable intrinsic discount estimate alongside a smaller gap to analyst targets, the key question is whether there is still an opportunity for investors here or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 15.3% Overvalued Arrowhead’s most followed narrative pegs fair value at about $64.08 a share, which sits below the last close of $73.91 and frames the current optimism.  Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for innovative treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.  Read the complete narrative. Curious what kind of revenue path, margin profile, and earnings multiple are being used to turn that pipeline story into a $64 fair value tag? The core narrative leans on specific assumptions about how quickly those programs scale and what investors might be willing to pay for that profit stream. Result: Fair Value of $64.08 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still meaningful risk from partner dependent milestone revenue and rising R&D and SG&A costs if commercial uptake or approvals fall short of expectations. Find out about the key risks to this Arrowhead Pharmaceuticals narrative. Another Take: DCF Points the Other Way The narrative-based fair value of $64.08 suggests Arrowhead looks around 15% overvalued, yet our DCF model points in the opposite direction, with an estimate of $145.46 and the shares trading at a 49.2% discount. Which set of assumptions do you find more convincing for your own work? Look into how the SWS DCF model arrives at its fair value. ARWR Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arrowhead Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With such mixed signals on value, it makes sense to look beyond headlines and stress test the assumptions yourself before taking a position. To see what the market is currently optimistic about, review the 2 key rewards Looking for more investment ideas? If Arrowhead has your attention, do not stop here. The next portfolio upgrade could be sitting in plain sight if you are willing to scan for it.  Spot potential value opportunities before they hit everyone’s radar by running through our list of 54 high quality undervalued stocks. Strengthen the foundation of your holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (42 results). Turn steady income into a real focus by zeroing in on our hand picked 12 dividend fortresses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630343317","isCrawlerRequest":true}